Correlation Between Intracellular Interferon-gamma (IFN-gamma) Production by CD4+ and CD8+ Lymphocytes and IFN-gamma Gene Polymorphism in Patients with Type 2 Diabetes Mellitus and Latent Autoimmune Diabetes of Adults (LADA)
Overview
Biology
Affiliations
IFN-gamma is considered to be involved in the pathogenesis of diabetes mellitus. In this study, the presence of T/A mutation at position -874 in IFN-gamma gene was assessed in patients with latent autoimmune diabetes of adults (LADA), in patients with type 2 diabetes and in healthy individuals. Subsequently, an attempt was made to correlate the presence of this mutation with the ability of CD4+ or CD8+ lymphocytes from these individuals to release IFN-gamma following mitogenic stimulation. There were no significant differences in the distribution of genotypes and haplotypes in the three study groups. However, the frequency of the low IFN-gamma production allele (IFN-gamma 874( *)A) was significantly higher in type 2 diabetics compared to controls. CD4+ and CD8+ cells obtained from type 2 diabetics released significantly lower amounts of IFN-gamma in the intracellular space, compared to those released by cells obtained from LADA patients and healthy volunteers. Furthermore, even CD4+ and CD8+ from type 2 diabetics bearing the TT genotype (high producers) released significantly lower amounts of IFN-gamma than LADA patients carrying the same genotype, probably due to the activity of molecules directly or indirectly inhibiting IFN-gamma production. The results of this study indicate that IFN-gamma may contribute to the development of type 2 diabetes, based on a combination of molecular and immunological observations.
JAK1/2 Regulates Synergy Between Interferon Gamma and Lipopolysaccharides in Microglia.
Young A, Denovan-Wright E J Neuroimmune Pharmacol. 2024; 19(1):14.
PMID: 38642237 DOI: 10.1007/s11481-024-10115-z.
Altered serum levels of cytokines in patients with myasthenia gravis.
Wei S, Yang C, Si W, Dong J, Zhao X, Zhang P Heliyon. 2024; 10(1):e23745.
PMID: 38192761 PMC: 10772159. DOI: 10.1016/j.heliyon.2023.e23745.
Somersalo E, Kuuliala K, Kuuliala A, Wasenius N, Klemetti M, Kivimaki A Diabetes Ther. 2023; 14(8):1427-1436.
PMID: 37286850 PMC: 10299958. DOI: 10.1007/s13300-023-01428-y.
Sharbatdar Y, Mousavian R, Noorbakhsh Varnosfaderani S, Aziziyan F, Liaghat M, Baziyar P Inflammopharmacology. 2023; 31(3):1029-1052.
PMID: 37079169 PMC: 10116486. DOI: 10.1007/s10787-023-01215-y.
Qureshi N, Desousa J, Siddiqui A, Drees B, Morrison D, Qureshi A Int J Mol Sci. 2023; 24(3).
PMID: 36769056 PMC: 9916932. DOI: 10.3390/ijms24032732.